Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
CTO
Citius Oncology, Inc.CTOR
-77.7%+7,484pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-13.3%-888pp
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-3.6%-1.6pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-10.8%-2.6pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-24.9%-110pp

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s earnings yield?
TuHURA Biosciences, Inc. (HURA) reported earnings yield of -30.6% in Q1 2026.
How has TuHURA Biosciences, Inc.'s earnings yield changed year-over-year?
TuHURA Biosciences, Inc.'s earnings yield decreased by 77.9% year-over-year, from -17.2% to -30.6%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.